Current Mesothelioma News and Events

Current Mesothelioma News and Events, Mesothelioma News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 5 | 186 Results
Analysis: talc-based cosmetics test positive for asbestos
Laboratory tests of talc-based cosmetics products, commissioned by the Environmental Working Group, found asbestos -- a deadly human carcinogen for which there is no safe level of exposure -- in almost 15 percent of samples. (2020-11-25)

Trial targets deadly lung cancer
With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection in future. One novel approach, using natural therapeutic benefits of curcumin, a key component of the spice turmeric, will be put to the test in a clinical trial in 2021 as part of world-leading research at Flinders University. (2020-10-30)

Tiny golden bullets could help tackle asbestos-related cancers
Gold nanotubes - tiny hollow cylinders one thousandth the width of a human hair - could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers at the Universities of Cambridge and Leeds. (2020-10-26)

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize. Due to the differences in clinical prognosis and subsequent management strategies, in situ PAT associated with RT -- which has not previously been described in the English literature -- must be distinguished from pulmonary embolism. (2020-10-09)

checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium. (2020-08-08)

Shining light on a malignant lung cancer
Treating a rare type of malignant lung cancer could improve, thanks to near-infrared irradiation and a cancer-targeting compound. Nagoya University oncologist Kazuhide Sato and colleagues tested the treatment and published their findings in the journal Cells. (2020-06-20)

Novel treatment for mesothelioma shows promise for patients
novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14. (2020-06-15)

Chemotherapy/immunotherapy combo shows promise for first-line treatment of mesothelioma
Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. (2020-06-11)

Durvalumab added to standard chemotherapy improved overall survival in mesothelioma
PrECOG, LLC is reporting on its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma. The trial evaluated adding durvalumab, an immune checkpoint antibody targeting PD-L1, to pemetrexed and cisplatin chemotherapy in 55 patients of any histologic subtype. The study met its primary endpoint with a median overall survival of 20.4 months as compared to the historical control of 12.1 months. The combination was well-tolerated with no unexpected toxicities. (2020-05-20)

Two drugs used in combination prove to be effective against most aggressive asbestos cancer in mice
Currently, there are few effective treatments for malignant mesothelioma, although it has been decades since it was found that the major risk factor is exposure to asbestos. The drugs identified by CNIO researchers are being tested on other types of cancer, which can speed up clinical trials for mesothelioma. The authors identified molecular markers that could be used to determine which patients could benefit most from this new therapy, provided that it is approved. (2020-01-08)

Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant...
Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. Comparing NSCLC PE and published plasma levels of CAR-T recipients, both were dominated by sIL-6R and IL-6 but NSCLC PE had more VEGF, FGF2 and TNF, and less IL-2, IL-4, IL-13, IL-15, MIP1 and IFN. (2019-11-22)

Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant meso
Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. (2019-11-05)

Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. Data from the PROMISE-meso trial presented at the ESMO Congress 2019 highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response. (2019-09-30)

Asbestosis toxicity study identifies potential of novel mineral treatment
Scientists investigating the ability of a micronized mineral compound to counteract the carcinogenic effects of mesothelioma and asbestosis, say results from both cell culture and animal model studies are very promising, warranting further investigation, including the commencement of clinical trials. (2019-08-06)

Radiotherapy doubles survival for patients with mesothelioma
Mesothelioma patients are twice as likely to survive for two years or longer, if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented at the ESTRO 38 conference. (2019-04-28)

Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors
A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-03-31)

Cancer researchers highlight clinical potential of liquid biopsy using droplet digital PCR technology at the 2019 AACR Annual Meeting
Research studies supporting the clinical utility of droplet digital PCR powered liquid biopsy will be presented during this year's AACR Annual Meeting. (2019-03-29)

Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. (2019-03-29)

Genomics provide hope for those with 'one in a million' cancer diagnosis
New research has shown that many people with rare cancers can benefit from genomic profiling. The findings of the patient-driven trial are being presented today at the Clinical Oncology Society of Australia Annual Scientific Meeting and could result in dramatic changes to the way those with rare cancers are diagnosed and treated. (2018-11-13)

The body's defence mechanisms: Teamwork is key for cancer-fighting proteins
A new study published in Nature Communications shows that a molecular symbiosis between BAP1 and ASXL2 proteins can suppress cancerous tumors. (2018-10-25)

Otago discovery links DNA-packaging proteins and cancer development
University of Otago scientists have unravelled the 3D structure of two proteins, potentially providing answers as to why some people may be at risk of developing specific cancers. (2018-09-26)

Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor gene in kidney, eye, bile duct, mesothelioma and other cancers by regulating a form of cell death called ferroptosis, opening up a potential new area of therapy research. Findings from the study, led by Boyi Gan, Ph.D., associate professor, Department of Experimental Radiation Oncology, were published in the Sept. 10 online issue of Nature Cell Biology. (2018-09-10)

Study finds how NF-2 gene mutations make cells hyper-responsive to growth factor signaling
A team of Massachusetts General Hospital (MGH) Cancer Center researchers has determined one way that mutations in a gene involved in a rare, hereditary cancer syndrome lead to out-of-control cellular proliferation. (2018-08-28)

Increase in lifestyle-related cancers over past decade spotlights need for prevention
Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted. (2018-06-02)

Combination immunotherapy improves survival in mouse models of mesothelioma
Massachusetts General Hospital investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma. (2018-04-02)

Little evidence for any direct impact of national cancer policies on short-term survival in England
A study published by The BMJ today finds little evidence for any direct impact of national cancer policy initiatives implemented since 2000 on short term cancer survival in England. (2018-03-14)

Overlooked immune cells hold breakthrough for treating aggressive cancers
Medical University of South Carolina investigators report in the December 2017 issue of Nature Communications that adoptive T cell transfer (ACT) therapy, using CD4 T cells expressing elevated levels of the protein CD26, effectively regresses solid tumors. CD8 T cells are more commonly used for ACT therapy, because they are thought to be better cancer fighters. However, this study showed that CD4 T cells, expressing high CD26, resist death and are robustly effective at killing multiple tumor types. (2017-12-19)

Subset of carbon nanotubes poses cancer risk similar to asbestos in mice
Researchers have shown for the first time in mice that long and thin nanomaterials called carbon nanotubes may have the same carcinogenic effect as asbestos: they can induce the formation of mesothelioma. The findings were observed in 10 percent -- 25 percent of the 32 animals included in the study, which has not yet been replicated in humans. The work appears Nov. 6 in Current Biology. (2017-11-06)

Landmark asbestos study published in The Lancet Public Health
A landmark study from The Australian National University into the health impacts of living in a house with loose-fill asbestos insulation has been published in the international journal The Lancet Public Health. (2017-11-01)

Early palliative care provides no quality of life benefits for recently diagnosed MPM patients
Early specialist palliative care for patients that were recently diagnosed with malignant pleural mesothelioma (MPM) does not impact quality of life (QOL) measures, according to research presented by Prof. Fraser Brims of Curtin University in Australia, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (2017-10-16)

Rare genetic cause of peritoneal mesothelioma points to targeted therapy
BWH investigators have uncovered a new genetic cause of mesothelioma: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma. Unlike previously known causes, this new discovery points to a potential therapeutic approach for those few patients whose tumors harbor the mutation. The team's findings are published in JAMA Oncology. (2017-09-14)

Scientific advances in thoracic oncology in 2016 highlighted by the IASLC
Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging and treatment in 2016, the International Association for the Study of Lung Cancer (IASLC) announces the second annual publication of 'Scientific Advances in Thoracic Oncology,' available online now and in the August 2017 issue of the IASLC's Journal of Thoracic Oncology (JTO). (2017-06-08)

Early research suggests first immunotherapy for mesothelioma on the horizon
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping treatment. There are currently no effective therapeutic options for patients with MPM. (2017-06-05)

Diagnosing cancer
Scientists have established a process for identifying biomarkers for the diagnosis of different types of cancer. With the aid of a specific type of infrared spectroscopy, the researchers applied an automated and label-free approach to detect tumor tissue in a biopsy or tissue sample. This, in turn, facilitates detailed protein analyses in the next step. (2017-04-03)

Pembrolizumab shows promise in treatment of mesothelioma
Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease. (2017-03-20)

New study finds arginine deprivation may be a useful strategy for treating bladder cancers
In a study published in The American Journal of Pathology, researchers report that more than 90% of all bladder cancers are deficient in argininosuccinate synthetase 1 (ASS1), an enzyme necessary for arginine synthesis, and patients with tumors having low ASS1 expression have shorter survival. Treatment with the arginine-degrading enzyme ADI-PEG 20 inhibited tumor growth in ASS1-deficient cells both in vivo and in vitro, suggesting a new therapeutic approach to bladder cancer is possible. (2016-12-12)

Squeezing life from DNA's double helix
USC scientists find DNA replication begins when the double helix, caught in a vice of proteins, melts. (2016-12-12)

Summary of research presented at the IASLC 17th World Conference on Lung Cancer
Today's press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on clinical trials that advance the progress made in lung cancer treatment through immunotherapy and better diagnostics. Abstracts and full versions of news releases for each topic covered are available through links in this summary, or through IASLC media representative Chris Martin. (2016-12-07)

Advocacy and community health care models complement research and clinical care
Global lung cancer researchers and patient advocates today emphasized that new models of delivering care and communicating about cancer care play an important role in the fight against lung cancer. Their remarks come on the first day of the IASLC 17th World Conference on Lung Cancer in Vienna, Austria. (2016-12-04)

Study examines association of asbestos exposure, mesothelioma in Eastern China
A new research letter published online by JAMA Oncology looks at asbestos exposure and malignant mesothelioma in Eastern China. (2016-12-01)

Page 1 of 5 | 186 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.